NASDAQ:ITRM

Iterum Therapeutics (ITRM) Stock Price, News & Analysis

Iterum Therapeutics logo
$0.03 0.00 (0.00%)
As of 11/6/2026

About Iterum Therapeutics Stock (NASDAQ:ITRM)

Advanced

Key Stats

Today's Range
$0.03
▼
$0.03
50-Day Range
$0.03
▼
$0.03
52-Week Range
$0.03
▼
$1.42
Volume
N/A
Average Volume
4.85 million shs
Market Capitalization
$1.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Reduce

Company Overview

Iterum Therapeutics plc is a pharmaceutical company focused on developing and commercializing antibiotics for bacterial infections, including infections caused by drug-resistant pathogens. The company is headquartered in Ireland and has focused its commercial efforts on the U.S. market.

Its lead product is sulopenem, a penem-class antibiotic developed in oral and intravenous formulations. The oral formulation, marketed as Orlynvah, combines sulopenem etzadroxil with probenecid.

In October 2024, the U.S. Food and Drug Administration approved Orlynvah for certain uncomplicated urinary tract infections in adult women who have limited or no alternative oral antibacterial treatment options. The approval marked a key step in Iterum’s efforts to bring its antibiotic to patients.

AI Generated. May Contain Errors.

Receive ITRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ITRM Stock News Headlines

Beyond NVDA: The World’s Next #1 Company?
This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all.tc pixel
Iterum Therapeutics Provides Business Update
Iterum Therapeutics PLC
See More Headlines

ITRM Stock Analysis - Frequently Asked Questions

Iterum Therapeutics' stock was trading at $0.3350 on January 1st, 2026. Since then, ITRM stock has decreased by 91.0% and is now trading at $0.03.

Iterum Therapeutics PLC (NASDAQ:ITRM) released its quarterly earnings data on Friday, November, 14th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.07. The firm had revenue of $390 thousand for the quarter.
Read the conference call transcript
.

Iterum Therapeutics shares reverse split before market open on Thursday, August 18th 2022.The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Iterum Therapeutics (ITRM) raised $92 million in an IPO on Friday, May 25th 2018. The company issued 6,150,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Iterum Therapeutics investors own include Atossa Genetics (ATOS), SNDL (SNDL), Tonix Pharmaceuticals (TNXP), NVIDIA (NVDA), NIO (NIO), 9 Meters Biopharma (NMTR) and Ideanomics (IDEX).

Company Calendar

Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ITRM
CIK
1659323
Fax
N/A
Employees
10
Year Founded
2015

Profitability

EPS (Trailing Twelve Months)
($0.75)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$24.77 million
Net Margins
N/A
Pretax Margin
-6,842.31%
Return on Equity
N/A
Return on Assets
-65.54%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.13
Quick Ratio
1.96

Sales & Book Value

Annual Sales
$390 thousand
Price / Sales
4.10
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.15) per share
Price / Book
-0.20

Miscellaneous

Outstanding Shares
53,292,000
Free Float
52,226,000
Market Cap
$1.60 million
Optionable
Not Optionable
Beta
2.96

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:ITRM) was last updated on 11/6/2026 by MarketBeat.com Staff.
From Our Partners